Free Trial
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

iTeos Therapeutics logo
$8.22 -0.13 (-1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$8.40 +0.18 (+2.18%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Key Stats

Today's Range
$8.12
$8.44
50-Day Range
$5.04
$8.41
52-Week Range
$4.80
$18.30
Volume
1.97 million shs
Average Volume
561,932 shs
Market Capitalization
$314.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.86
Consensus Rating
Hold

Company Overview

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

iTeos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

ITOS MarketRank™: 

iTeos Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 402nd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    iTeos Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about iTeos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iTeos Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iTeos Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    iTeos Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.64% of the float of iTeos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    iTeos Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in iTeos Therapeutics has recently increased by 25.25%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    iTeos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    iTeos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.64% of the float of iTeos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    iTeos Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in iTeos Therapeutics has recently increased by 25.25%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    iTeos Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    7 people have searched for ITOS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,396,703.00 in company stock.

  • Percentage Held by Insiders

    12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iTeos Therapeutics' insider trading history.
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITOS Stock News Headlines

What is Leerink Partnrs' Estimate for ITOS Q2 Earnings?
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Research Analysts Issue Forecasts for ITOS Q2 Earnings
See More Headlines

ITOS Stock Analysis - Frequently Asked Questions

iTeos Therapeutics' stock was trading at $7.68 on January 1st, 2025. Since then, ITOS stock has increased by 7.0% and is now trading at $8.22.
View the best growth stocks for 2025 here
.

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Monday, April, 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14.

iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of iTeos Therapeutics include RA Capital Management L.P. (9.53%), BVF Inc. IL (8.03%), 683 Capital Management LLC (4.57%) and Goldman Sachs Group Inc. (1.53%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Matthew Gall and David Hallal.
View institutional ownership trends
.

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
4/28/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.86
High Stock Price Target
$46.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+117.2%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-112,640,000.00
Pretax Margin
-320.49%

Debt

Sales & Book Value

Annual Sales
$35 million
Price / Cash Flow
N/A
Book Value
$16.08 per share
Price / Book
0.51

Miscellaneous

Free Float
31,967,000
Market Cap
$314.61 million
Optionable
Optionable
Beta
1.39
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:ITOS) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners